Ozempic Generic Approval: OneSource and Hikma's Strategic Collaboration in Saudi Arabia
Regulatory Approval for Ozempic Generic in Saudi Arabia
OneSource Specialty Pharma Ltd. on Wednesday announced that it has received regulatory clearance from Saudi Arabia to launch its ozempic generic, the blockbuster semaglutide therapy used for diabetes and weight loss.
Strategic Partnership with Hikma Pharmaceuticals
With approval from the Saudi Food and Drug Authority, OneSource aims to commercialize its generic version through its exclusive regional partner Hikma Pharmaceuticals Plc, the largest drugmaker in the Middle East and North Africa by sales. This partnership is set to expand OneSource's reach into one of the fastest-growing GLP-1 markets globally.
- Neeraj Sharma, CEO of OneSource, stated, "We are extremely excited to secure SFDA approval for semaglutide in Saudi Arabia, which has a significant long-term potential."
- The collaboration aims to address increasing obesity and Type 2 diabetes rates in the region.
- OneSource has been enhancing its capabilities in biologics and drug-device combination manufacturing.
Commercial Potential and Future Plans
As demand for GLP-1 therapies accelerates, OneSource's production of semaglutide at its Bengaluru facility will cater to both private and institutional customers through Hikma’s extensive sales and distribution network.
This critical partnership not only strengthens OneSource's position in the global contract development and manufacturing (CDMO) landscape but also reinforces its strategy to deepen its global footprint.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.